IL312124A - Eukaryotic cells containing adenovirus polynucleotides - Google Patents

Eukaryotic cells containing adenovirus polynucleotides

Info

Publication number
IL312124A
IL312124A IL312124A IL31212424A IL312124A IL 312124 A IL312124 A IL 312124A IL 312124 A IL312124 A IL 312124A IL 31212424 A IL31212424 A IL 31212424A IL 312124 A IL312124 A IL 312124A
Authority
IL
Israel
Prior art keywords
adenovirus
eukaryotic cells
associated virus
virus polynucleotides
polynucleotides
Prior art date
Application number
IL312124A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL312124A publication Critical patent/IL312124A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL312124A 2021-10-18 2022-10-18 Eukaryotic cells containing adenovirus polynucleotides IL312124A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256730P 2021-10-18 2021-10-18
PCT/US2022/078266 WO2023069926A1 (en) 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides

Publications (1)

Publication Number Publication Date
IL312124A true IL312124A (en) 2024-06-01

Family

ID=84389146

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312124A IL312124A (en) 2021-10-18 2022-10-18 Eukaryotic cells containing adenovirus polynucleotides

Country Status (11)

Country Link
US (2) US12234472B2 (https=)
EP (1) EP4419696A1 (https=)
JP (1) JP2024537896A (https=)
KR (1) KR20240099288A (https=)
CN (1) CN118103517A (https=)
AU (1) AU2022373653A1 (https=)
CA (1) CA3234939A1 (https=)
IL (1) IL312124A (https=)
MX (1) MX2024004647A (https=)
TW (1) TW202323529A (https=)
WO (1) WO2023069926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515999A (zh) 2023-06-20 2025-04-16 美商再生元醫藥公司 純化填充的腺相關病毒殼體之方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998054345A1 (en) 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
AU770005B2 (en) 1998-04-15 2004-02-12 Research Foundation Of The State University Of New York, The Selective regulation of adenovirus production
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6423544B1 (en) 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
MY123548A (en) 1999-11-08 2006-05-31 Shell Int Research Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1362096B1 (de) 2001-02-21 2009-08-19 CEVEC Pharmaceuticals GmbH Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1743041B1 (en) 2004-05-03 2012-06-27 Stefan Kochanek Modified viral vector particles
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2007084773A2 (en) * 2006-01-20 2007-07-26 University Of North Carolina At Chapel Hill Enhanced production of infectious parvovirus vectors in insect cells
EP2431469A3 (en) 2006-05-15 2012-05-30 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US8852926B2 (en) 2007-10-25 2014-10-07 Board Of Trustees Of Southern Illinois University Genetic selection system for identification of MicroRNA target genes
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
SG187863A1 (en) 2010-08-16 2013-03-28 Cevec Pharmaceuticals Gmbh Permanent human amniocyte cell lines for producing influenza viruses
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
ES2698610T3 (es) 2013-08-06 2019-02-05 Lonza Biologics Plc Medios y métodos para la generación de células productoras de mamífero para la producción de proteínas recombinantes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
EP4410805A3 (en) 2014-03-18 2024-11-27 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
KR102243243B1 (ko) 2014-10-23 2021-04-22 리제너론 파마슈티칼스 인코포레이티드 신규한 cho 통합 부위 및 이의 용도
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3205719A1 (en) 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603577D0 (en) 2016-03-01 2016-04-13 Oxford Genetics Ltd Promoter
MX2018011928A (es) 2016-03-30 2019-03-28 Spark Therapeutics Inc Linea celular para produccion de proteina recombinante y/o vector viral.
US11512144B2 (en) 2016-04-20 2022-11-29 Regeneran Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing loci
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
US20190171188A1 (en) 2016-08-10 2019-06-06 Lonza Inc. Biopharmaceutical Batch Recipe Review by Exception
JP7112414B2 (ja) 2017-02-08 2022-08-03 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ８８
WO2018150269A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
KR20190129092A (ko) 2017-03-17 2019-11-19 론자 리미티드 자동화된 배치 데이터 분석
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
US10858631B2 (en) 2017-04-18 2020-12-08 Glaxosmithkline Intellectual Property Development Limited Methods for adeno-associated viral vector production
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
WO2019073059A1 (en) 2017-10-12 2019-04-18 Freeline Therapeutics Limited ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV
JP7274225B2 (ja) 2017-10-25 2023-05-16 ノイスコム アーゲー 真核細胞系統
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
WO2019157239A1 (en) 2018-02-08 2019-08-15 David Kiewlich Plasmid vectors for expression of large nucleic acid transgenes
GB201802122D0 (en) 2018-02-09 2018-03-28 Univ Oxford Innovation Ltd Product and use
GB201814590D0 (en) 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
EP3597172A1 (en) 2018-07-16 2020-01-22 Kao Germany GmbH Hair treatment composition
WO2020041454A1 (en) 2018-08-21 2020-02-27 Lonza Ltd A process for creating reference data for predicting concentrations of quality attributes
GB201814141D0 (en) 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
JP7549582B2 (ja) 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
WO2020077411A1 (en) 2018-10-17 2020-04-23 Children's Medical Research Institute Nucleic acid molecules and methods for aav vector selection
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
KR20210108406A (ko) 2018-12-21 2021-09-02 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
AU2019403279A1 (en) 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
GB201902068D0 (en) 2019-02-14 2019-04-03 Cambridge Entpr Ltd Methods of reactivating proliferative capacity non-proliferative tissues
CN113544509A (zh) 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
AU2020270960B2 (en) 2019-04-12 2026-01-29 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
CA3138576A1 (en) 2019-05-16 2020-11-19 Trustees Of Boston University Regulated synthetic gene expression systems
AU2020284255A1 (en) 2019-05-30 2022-01-06 Solid Biosciences Inc. Recombinant herpesvirales vector
KR20220118436A (ko) 2019-12-19 2022-08-25 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
WO2021146591A2 (en) 2020-01-17 2021-07-22 Asklepios Biopharmaceutical, Inc. Recombinant aav production
MX2022009560A (es) 2020-02-04 2022-09-09 Oxford Genetics Ltd Proceso de fabricacion de vectores virales adenoasociados.
GB202001484D0 (en) 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method
JP2023518415A (ja) 2020-03-19 2023-05-01 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法
JP2023526348A (ja) 2020-05-15 2023-06-21 アイヴェックスソル インコーポレイテッド 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
US20230279427A1 (en) 2020-07-24 2023-09-07 Regents Of The University Of Minnesota Cell lines for recombinant aav production and aav-implemented protein production
WO2022038367A1 (en) 2020-08-21 2022-02-24 Oxford Genetics Limited Process for making a recombinant aav library
GB202013057D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Method of making recombinant aavs
GB202013060D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Cell line
EP4006141A1 (en) 2020-11-25 2022-06-01 CEVEC Pharmaceuticals GmbH Method for the production of aav
WO2022173944A1 (en) 2021-02-11 2022-08-18 Lonza Houston, Inc. Adeno-associated virus (aav) production
WO2022223954A1 (en) 2021-04-19 2022-10-27 Oxford Genetics Limited Dna amplification method using care elements
US20230257831A1 (en) 2021-09-01 2023-08-17 Oxford Genetics Limited Method for determining aav titre
MX2024004691A (es) 2021-10-18 2024-05-23 Regeneron Pharma Transcripcion controlada de polinucleotidos.
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
WO2023173105A2 (en) 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production

Also Published As

Publication number Publication date
CA3234939A1 (en) 2023-04-27
US20230193312A1 (en) 2023-06-22
EP4419696A1 (en) 2024-08-28
MX2024004647A (es) 2024-05-02
KR20240099288A (ko) 2024-06-28
JP2024537896A (ja) 2024-10-16
AU2022373653A1 (en) 2024-05-02
US20250154524A1 (en) 2025-05-15
US12234472B2 (en) 2025-02-25
WO2023069926A1 (en) 2023-04-27
TW202323529A (zh) 2023-06-16
CN118103517A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
IL279157A (en) Circular RNA for translation in eukaryotic cells
EP3331067A4 (en) Cathode active material for secondary battery, and secondary battery comprising same
EP3386015A4 (en) Cathode active material for secondary battery, and secondary battery comprising same
HUE067222T2 (hu) Katódaktív anyag másodlagos akkumulátorhoz és azt tartalmazó másodlagos akkumulátor
EP3386009A4 (en) Positive electrode active material for secondary battery, positive electrode, for secondary battery, comprising same, and secondary battery
EP3331072A4 (en) Composition for forming secondary battery cathode, and secondary battery cathode and secondary battery, which are manufactured using same
EP3249723A4 (en) Cathode active material for secondary battery and secondary battery comprising same
EP3305753A4 (en) LITHIUM SALT COMPOUND, WATER-FREE ELECTROLYTE SOLUTION USING THEREOF, LITHIUM ION SECONDARY BATTERY AND LITHIUM ION CONDENSER
EP3358662A4 (en) Binder composition, non-aqueous electrolyte secondary battery electrode, and non-aqueous electrolyte secondary battery
EP3273519A4 (en) Non-aqueous electrolyte, and non-aqueous electrolyte secondary cell
EP3276735A4 (en) Nonaqueous electrolyte for sodium secondary cell, and sodium secondary cell
LT3551960T (lt) Zonos blokavimo ryšio delsos kompensavimas
EP3595059A4 (en) POSITIVE ELECTRODE ACTIVE MATERIAL, AND CELL
EP3258529A4 (en) Nonaqueous-electrolyte secondary cell, and positive electrode of nonaqueous-electrolyte secondary cell
EP3252861A4 (en) Non-aqueous electrolyte solution, and non-aqueous-electrolyte secondary cell using same
IL290037A (en) Ergothioneine, s-methyl-ergothioneine and their uses
EP3282502A4 (en) Electrode, electrode group and nonaqueous electrolyte battery
EP3309882A4 (en) Cathode composition, cathode and fuel cell including same
IL312124A (en) Eukaryotic cells containing adenovirus polynucleotides
EP3357123A4 (en) SODIUM-METAL BATTERIES WITH INTERCALATE CATHODE
GB2617521B (en) Improved electrode arrangement
GB201810165D0 (en) Surgical assembly, system and electrode assembly
EP3970740A4 (en) CELL FUSION-INDUCING VACCINIA VIRUS AND USE THEREOF
HK40113202A (en) Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP3255709A4 (en) Positive electrode active material and secondary battery comprising same